Shares in Anglo-Swedish drug major AstraZeneca (LSE: AZN) dropped nearly 4% in morning trade on the London Stock Exchange as the company warned full year 2016 revenue and earnings will take a hit on the back of generic competition for its cholesterol drug Crestor (rosuvastatin).
Chief executive Pascal Soriot said: “As we face the transitional period of patent expiry for Crestor in the US, we’re confident that our strong execution on strategy, combined with the benefits of focused investments and new launches, keeps us on track to return to sustainable growth in line with our targets.”
The company said it sees low-to-mid single digit decline in revenue and earnings for 2016. In addition, the currency headwinds are expected to add to the impact by 3%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze